When chemotherapy is recommended, it is natural to wonder why one combination of medicines has been chosen over another. Is it based on the type of cancer, its stage, test results, or the patient's general health?
In reality, choosing a chemotherapy regimen involves bringing several pieces of information together. This is why good cancer treatment planning is personal rather than standardised.
Before recommending treatment, an oncologist may consider:
- The cancer: Its type, stage, location and biological characteristics.
- The patient: Age, general health, blood counts, kidney and liver function, and previous treatments.
- The treatment goal: Whether chemotherapy is being used before surgery, after surgery, to control cancer or as part of a wider treatment plan.
The aim is to select a treatment approach that is clinically appropriate while taking the patient's individual circumstances into account.
It Begins with a Detailed Assessment
A chemotherapy decision usually follows a careful review of the diagnosis. The oncologist may examine pathology reports, scans, blood tests and previous medical records before discussing treatment.
The stage and characteristics of the cancer are particularly important. Previous chemotherapy or other treatments also matter because they can influence which medicines remain suitable. The National Cancer Institute notes that the type and extent of cancer, previous chemotherapy and other health conditions are among the key factors doctors consider when selecting chemotherapy.
The treatment plan may take into account:
Type and stage
The same broad cancer type can require different approaches depending on where it is located and how far it has progressed.
Previous treatment
Medicines already received, along with surgery, radiotherapy or other therapies, can influence the next step.
Treatment objective
Chemotherapy may be used to reduce the size of a tumour, lower the risk of recurrence, treat cancer that has spread or work alongside another form of treatment.
Biomarkers Can Refine the Decision
Cancer treatment has become increasingly individualised. In suitable cases, biomarker testing can provide additional information about the characteristics of a tumour and whether certain treatments may be appropriate.
This is an important part of precision oncology. Biomarker testing may examine genes, proteins or other features of cancer cells. However, it is not necessary or useful in exactly the same way for every patient. Its relevance depends on the cancer and the clinical situation.
Why this information matters
- Treatment selection: Certain biomarkers may indicate whether targeted or other specialised treatments could be considered.
- Avoiding unsuitable options: Test results may also help doctors understand which treatments are less likely to be useful.
- A broader clinical picture: Biomarker results are considered alongside pathology, scans, stage and overall health rather than on their own.
This approach allows the oncologist to move beyond simply asking, "What cancer is this?" and consider, "What treatment characteristics does this particular cancer have?"
The Patient's Health Is Equally Important
Two people with a similar diagnosis may not receive identical chemotherapy. Their ability to tolerate treatment can be different, which is why the patient's health forms an important part of treatment planning.
Several factors are reviewed before treatment
Kidney and liver function
Blood tests can show how well these organs are functioning. This information may influence medicine selection or dosing.
Blood counts
Red cells, white cells and platelets are checked because chemotherapy can affect the bone marrow. Results can help determine whether treatment can proceed as planned.
Other health conditions
Conditions affecting the heart, kidneys, liver or other organs may need to be considered when selecting treatment.
Current medicines
The oncology team should know about prescription medicines, over-the-counter medicines and supplements because some may interact with cancer treatment.
At IOHC, pre-treatment monitoring includes investigations such as CBC, platelet count, serum creatinine and liver function testing, supporting treatment decisions and ongoing monitoring.
How Is the Chemotherapy Schedule Decided?
Once the clinical information has been reviewed, the oncologist determines the medicines, doses and timing. Some regimens use a single medicine, while others combine several medicines that work in different ways.
Chemotherapy is often given in cycles, with treatment followed by a recovery period. The exact schedule depends on the cancer, the medicines being used and the treatment objective.
| Treatment decision | Factors considered |
|---|---|
| Medicines | Cancer type, stage and biology |
| Dose | Health, organ function and blood counts |
| Timing | Medicine and treatment protocol |
| Number of cycles | Treatment goal and response |
| Monitoring | Blood tests, scans and clinical assessment |
This is why there is rarely a single answer to the question, "How many chemotherapy sessions will I need?" The number and frequency can vary considerably from one patient to another.
Treatment Is Monitored, Not Simply Prescribed
A treatment plan can evolve as treatment progresses. The oncology team may monitor blood tests, symptoms, side effects and response to treatment before deciding whether to continue with the same dose and schedule.
Adjustments may sometimes be needed
- Side effects: A dose may need to be modified or a treatment delayed if the body needs more time to recover.
- Blood or organ function: Changes in test results may require the treatment plan to be reviewed.
- Response: Scans and clinical assessments may help determine whether the current approach remains appropriate.
A change in treatment does not automatically mean that chemotherapy is not working. It can reflect careful monitoring and an effort to maintain the right balance between treatment and tolerability.
Why Specialist Experience Matters
The science behind chemotherapy is supported by clinical evidence and established treatment protocols, but applying that evidence to an individual patient requires clinical judgement.
This is particularly relevant when a patient has a complex diagnosis, previous treatment or more than one possible treatment approach. The oncology team may also work with specialists from other disciplines when required.
The legacy of Dr Suresh Advani chemotherapy care is closely associated with decades of oncology practice and the development of personalised cancer care in India. IOHC continues this philosophy through specialist consultations, personalised treatment planning, chemotherapy, targeted therapy, immunotherapy and precision oncology.
What Should Patients Ask Their Oncologist?
A treatment consultation should give patients an opportunity to understand not only what is being recommended, but why.
Before starting treatment, it can be useful to ask:
- What is the main goal of my chemotherapy?
- Why has this particular combination been recommended?
- Are any biomarker or molecular test results influencing the decision?
- How many cycles are expected?
- What monitoring will I need between treatments?
- Which side effects should I report immediately?
- Would a second opinion be useful in my situation?
Having these questions ready can make the consultation more productive and give patients a clearer understanding of the road ahead.
Personalised Planning Makes Every Decision Count
There is no universal chemotherapy plan. The right approach depends on the cancer, its stage and biology, previous treatment, overall health and the goals of care.
For patients exploring chemotherapy treatment planning Mumbai options, a detailed specialist consultation can provide clarity before treatment begins. If you or a loved one has been advised to undergo chemotherapy, take the opportunity to understand the proposed regimen, ask questions and discuss the available options with an experienced oncology team. At IOHC, personalised treatment planning brings together specialist expertise, diagnostic review, chemotherapy and supportive care in one coordinated setting.
Frequently Asked Questions
How do doctors choose the right chemotherapy?
The oncologist considers the type and stage of cancer, previous treatment, overall health and the intended treatment outcome. The proposed cancer treatment plan is then tailored to the individual.
Medical history: Previous treatments and existing health conditions can influence the choice.
Treatment objective: The purpose of chemotherapy helps determine the medicines and schedule.
Does chemotherapy depend on the stage of cancer?
Yes. The stage can influence whether chemotherapy is recommended and how it fits into the wider treatment plan. However, stage is only one part of the decision.
Cancer characteristics: Pathology and tumour biology also provide important information.
Overall health: The patient's ability to tolerate treatment is considered alongside the stage.
Are blood tests needed before chemotherapy?
Blood tests are commonly used before treatment to assess blood counts and organ function. They help the oncology team determine whether treatment can be given safely.
Blood counts: White cells, red cells and platelets may be monitored.
Organ function: Kidney and liver tests can help guide dosing and treatment decisions.
Can a chemotherapy dose be changed during treatment?
Yes. The dose or timing may sometimes be adjusted according to side effects, blood results, organ function or treatment response.
Monitoring: Regular assessments help the team identify changes early.
Individual response: Treatment can be modified when clinically appropriate rather than following a fixed approach.
What is precision oncology in cancer treatment?
Precision oncology uses information about the characteristics of a tumour to help guide treatment where appropriate. Biomarker testing may identify features that influence treatment selection.
Tumour testing: Depending on the cancer, doctors may examine genes, proteins or other biomarkers.
Personalised decisions: Results are interpreted alongside stage, pathology and the patient's overall health.
Published on Oct 05, 2026 • 8 min read
